IRL1620, a truncated analog of ET-1, is the smallest ETB-selective agonist that has been shown to selectively and transiently increase tumor blood flow Gulati et al., 2012, making it a potential adjuvant cancer therapy for enhancing the delivery of anti-tumor drugs and acute ischemic stroke Ranjan and Gulati, 2022. This evidence concerns the gene EDNRB and neoplasm.